The Technical Analyst
Accolade, Inc. [ACCD]
Exchange: NASDAQ Sector: Healthcare Industry: Health Information Services
Accolade, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-0.44% $9.13
America/New_York / 19 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 706.73 mill |
| EPS: | -1.620 |
| P/E: | -5.64 |
| Earnings Date: | Apr 25, 2024 |
| SharesOutstanding: | 77.41 mill |
| Avg Daily Volume: | 0.608 mill |
| RATING 2024-04-19 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Neutral | |
| Return On Equity: | Sell | |
| Return On Asset: | Neutral | |
| DE: | Strong Buy | |
| P/E: | Strong Sell | |
| Price To Book: | Neutral |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -5.64 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| 0x |
| Company: PE -5.64 | industry: PE -4.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
| N/A |
| N/A |
| Expected Trading Range (DAY) |
|---|
|
$ 8.61 - 9.65 ( +/- 5.67%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-04-18 | Hilton Michael W | Buy | 331 | Common Stock |
| 2024-04-18 | Hilton Michael W | Sell | 331 | Restricted Stock Units |
| 2024-04-17 | Barnes Stephen H. | Buy | 414 | Common Stock |
| 2024-04-18 | Barnes Stephen H. | Sell | 109 | Common Stock |
| 2024-04-17 | Barnes Stephen H. | Sell | 414 | Restricted Stock Units |
| INSIDER POWER |
|---|
| 13.46 |
| Last 100 transactions |
| Buy: 47 360 | Sell: 35 872 |
Forecast:
16:00 - $9.13
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $9.13
Forecast 2: 16:00 - $9.13
Forecast 3: 16:00 - $9.13
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $9.13 (-0.44% ) |
| Volume | 0.831 mill |
| Avg. Vol. | 0.608 mill |
| % of Avg. Vol | 136.82 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For ACCD
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $13.32 | N/A | Active |
|---|
ACCD
Accolade, Inc., together with its subsidiaries, develops and provides technology-enabled solutions that help people to understand, navigate, and utilize the healthcare system and their workplace benefits in the United States. The company offers a platform with cloud-based technology and multimodal support from a team of health assistants and clinicians, including nurses, physician medical directors, and behavioral health specialists. It also provides second opinion consultation and health care decision support services. The company serves employers who provide their employees and their employees' families a single place to turn for their health, healthcare, and benefits needs. Accolade, Inc. was incorporated in 2007 and is headquartered in Plymouth Meeting, Pennsylvania.
Latest Press Releases
2024-03-20 09:00:00 - Press Release
Accolade Wins 2024 Artificial Intelligence Excellence Award
Award recognizes the innovative blend of ai technology with an empathetic human approach to deliver exceptional healthcare experiences for members seattle , march 20, 2024 /prnewswire/ -- accolade, inc. (nasdaq: accd) today announced it has been named a winner of the business intelligence group's artificial intelligence excellence awards program for its application of natural language processing. this award recognizes companies leveraging ai technology to solve real-world problems.
2024-03-19 15:00:00 - Press Release
National Accolade Bestowed On Arkansas-based Provider: ‘best Rural High Speeds'
Little rock, ark.--(business wire)--in an industry where connection and quality of service matter most, arkansas-based kinetic was recognized and honored by forbes home for its “best rural high speeds” in the recent article “best internet options for rural areas of 2024.” this forbes home accolade is a testament to kinetic's pledge to bring affordable, fast and reliable internet to rural areas. kinetic was selected by a team of forbes home licensed professionals comparing 38 attributes across 2.
2024-03-19 09:00:00 - Press Release
Accolade Promotes Kelsi Mcdonald Harris To Chief People Officer
Mcdonald harris assumes new role on executive leadership team to deliver an exceptional employee experience and support the growth and development of its 2,400+ global workforce seattle , march 19, 2024 /prnewswire/ -- accolade, inc. (nasdaq: accd) announced today the promotion of kelsi mcdonald harris as chief people officer and senior vice president. "transforming healthcare in this country requires visionary human resources leaders who are willing to challenge the status quo," said rajeev singh, chairman and ceo at accolade.
2024-02-28 08:00:00 - Press Release
Accolade To Present At Upcoming Investor Conferences
Seattle, feb. 28, 2024 (globe newswire) -- accolade, inc. (nasdaq: accd) today announced that it will be presenting at the following upcoming investor conferences:
2024-02-27 09:00:00 - Press Release
Accolade Welcomes Brightline To Trusted Partner Ecosystem
Partnership expands access to high-quality, affordable adolescent and children's behavioral health services seattle , feb. 27, 2024 /prnewswire/ -- accolade, inc. (nasdaq: accd) announced today that brightline, a comprehensive pediatric behavioral health solution built for children, teens, their parents, and caregivers, has joined the company's trusted partner ecosystem. the brightline partnership builds on accolade's existing behavioral health partnerships with headspace, lyra, and equip and internal capabilities, including an in-house behavioral health advocacy team, accolade care therapists, and consulting psychiatrists.
Latest News
2024-04-05 06:34:44 - Seeking Alpha
Accolade: Staying Bullish On Favorable Developments
I like Accolade's choice of new partners added year-to-date, as I think the services provided by these partners will be well received by its clients' employees. ACCD's latest "Artificial Intelligence Excellence Award" presented by the Business Intelligence Group provides a validation of the potential AI-related tailwinds for the company. A review of Accolade's most recent developments leaves me bullish on the stock.
2024-03-12 08:56:12 - Proactive Investors
Chesapeake Bank receives AARP accolade for combatting financial exploitation
Chesapeake Financial Shares Inc. (OTCQX:CPKF)'s Chesapeake Bank was honored by the American Association of Retired Persons (AARP) for its steadfast efforts in combatting financial exploitation. On March 6, AARP revealed the recognition of Chesapeake Bank among a cohort of 166 banks, credit unions, and financial advisory firms bestowed with the prestigious BankSafe Trained Seal.
2024-02-28 08:00:00 - GlobeNewsWire
Accolade To Present at Upcoming Investor Conferences
SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the following upcoming investor conferences:
2024-02-23 14:14:40 - InvestorPlace
Alabama's Fertility Ruling Raises Challenges for Stocks of Fertility Benefits Providers
This week brought another blow for reproductive rights in the U.S. An Alabama Supreme Court handed down a ruling that not only can frozen embryos be classified as “children,” but destroying them can lead to charges of wrongful death. This decision has prompted the University of Alabama at Birmingham, the state's largest healthcare provider, to cease all in vitro fertilization (IVF) treatments.
2024-02-05 10:56:09 - Zacks Investment Research
Does Accolade (ACCD) Have the Potential to Rally 25.58% as Wall Street Analysts Expect?
The consensus price target hints at a 25.6% upside potential for Accolade (ACCD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-01-29 07:31:04 - Zacks Investment Research
4 Top Stocks That Flaunt Solid Earnings Acceleration
Invest in stocks such as AxoGen (AXGN), Western Digital (WDC), Accolade (ACCD) and Credo Technology (CRDO) for superb earnings acceleration.
2024-01-19 10:56:31 - Zacks Investment Research
Wall Street Analysts Predict a 26.85% Upside in Accolade (ACCD): Here's What You Should Know
The consensus price target hints at a 26.9% upside potential for Accolade (ACCD). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
2024-01-19 09:41:10 - Zacks Investment Research
Why Accolade (ACCD) Stock Might be a Great Pick
Accolade (ACCD) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
2024-01-17 03:23:06 - Seeking Alpha
Accolade: Remain Confident That FY25 Guided Growth Is Achievable
I continue to recommend a buy rating with a projected 20% growth in FY25. Recent results show that Accolade beat consensus estimates for revenue and EBITDA, and management expects 20% revenue growth and 2-4% EBITDA margins in FY25. Tailwinds for growth include strong demand for navigation solutions, the health plan channel strategy, GLP-1 growth catalyst, and the recovery in demand for expert medical opinion.
2024-01-02 08:00:00 - GlobeNewsWire
Accolade To Present at Upcoming Investor Conferences
SEATTLE, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Accolade, Inc. (NASDAQ: ACCD) today announced that it will be presenting at the following upcoming investor conferences: